Evidence map›Paper›PMID 35949279›Full record

ArticleObesity science & practice2022

Differences in mortality rate among patients hospitalized with severe COVID-19 according to their body mass index.

Alejandra Albarrán-Sánchez, Claudia Ramírez-Rentería, Juan C Anda-Garay, Maura E Noyola-García, Paolo Alberti-Minutti, Guillermo Flores-Padilla, Luis A Guizar-García, Carlos E Contreras-García, Daniel Marrero-Rodríguez, Keiko Taniguchi-Ponciano and 2 more

Open access · goldAbstract read
In one paragraph

Article in Obesity science & practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Alejandra Albarrán-SánchezServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0003-2693-4031
Claudia Ramírez-RenteríaUnidad de Investigación Médica en Enfermedades Endocrinas Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0003-3025-8339
Juan C Anda-GarayServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0003-0290-2078
Maura E Noyola-GarcíaServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.
Paolo Alberti-MinuttiServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0003-3998-3924
Guillermo Flores-PadillaServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0003-0697-620X
Luis A Guizar-GarcíaServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0001-6914-6815
Carlos E Contreras-GarcíaServicio de Medicina Interna del Hospital de Especialidades Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0002-3860-6791
Daniel Marrero-RodríguezUnidad de Investigación Médica en Enfermedades Endocrinas Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0001-5311-6654
Keiko Taniguchi-PoncianoUnidad de Investigación Médica en Enfermedades Endocrinas Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0003-1623-7398
Moises MercadoUnidad de Investigación Médica en Enfermedades Endocrinas Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0002-4748-9734
Aldo Ferreira-HermosilloUnidad de Investigación Médica en Enfermedades Endocrinas Centro Médico Nacional Siglo XXI Mexico City Mexico.ORCID https://orcid.org/0000-0002-5159-9856
Centro Medico Nacional Siglo XXI · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Obesity has been described as a risk factor for COVID-19 severity and mortality. Previous studies report a linear association between BMI and adverse outcomes, meanwhile in other critical illness, excessive fat tissue is related to improved survival. Whether different BMI is related with the survival of patients with severe COVID-19 deserves further analysis. Objective: To determine the mortality rate among hospitalized patients with severe COVID-19 stratified according to BMI. Methods: The clinical files of all patients hospitalized from March to December 2020 with a positive PCR test for SARS-CoV-2 discharged due to improvement or death, were analyzed. A mixed effects logistic regression was carried out to determine which clinical and biochemical characteristics and comorbidities were associated with in-hospital mortality. Results: The cohort consisted of 608 patients with a median age of 59 years (interquartile ranges, IQR 46-69 years), median BMI of 28.7 kg/m Conclusions: The patients in the underweight/overweight and grade 3 obesity categories are at higher risk of COVID-19 related mortality, compared to those with grade I or II obesity.

Indexed as

body weightCOVID‐19mortalityobesitySARS‐CoV‐2

Identifiers

PMID35949279
PMCPMC9358728
OpenAlexW4200214944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.